

Global Leprosy Strategy 2016–2020



Accelerating towards a leprosy-free world

Monitoring and Evaluation Guide



Global Leprosy Strategy 2016–2020

Accelerating towards a leprosy-free world

Monitoring and Evaluation Guide



Global Leprosy Strategy 2016–2020. Accelerating towards a leprosy-free world. Monitoring and Evaluation Guide

ISBN: 978-92-9022-549-2

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization..

Suggested citation. Global Leprosy Strategy 2016–2020. Accelerating towards a leprosy-free world. Monitoring and Evaluation Guide. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.


Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Photos courtesy of The Leprosy Mission England and Wales; Institute Lauro De Souza Lima, WHO collaborating centre; Bauru-SP, Brazil; Damien Foundation Belgium; and Ed Hanley – photographer and videographer, Toronto, Canada.

Contents



Annexes

1.	Patient card	.64
2.	Annexes	.64
3.	Leprosy register	.70
4.	Disability register	.71
5.	Contact register	.73
6.	Drug resistance register	74
7.	Critical incident investigation	.75
8.	Checklists for supervision	.79
9.	Programme evaluation process checklist	.87
10.	Participatory scale	.88
11.	Five-point scale for stigma assessment	.90



List of Contributors

Dr Yasin Al-Qubati Ms Kerstin Beise Dr Rosa Castalia Professor Emmanuelle Cambau Dr Bertrand Cauchoix Dr Erwin Cooreman Dr Rita Djupuri Dr Osman El Tayeb Dr Albis Francesco Gabrielli Mr Pete Garrat Dr Laura Gillini Professor Mohan Gupte Ms Deanna Hagge Mr Tesfaye Tadesse Haile Professor Eliane Ignotti Dr Herman-Joseph Kawuma

Dr Padebettu Krishnamurthy Dr Pim Kuipers Dr Jean Norbert Mputu Dr Uzoma Nwankwo Dr Basudev Pandey Dr Vijay Kumar Pannikar Dr V.R.R. Pemmaraju Professor Jan Hendrik Richardus Dr Paul Saunderson Professor W. Cairns Smith Ms Hiroe Soyagimi Dr Nayani Suriyarachchi Dr Wim van Brakel Ms Vivian Velema-Andyka Professor Mitchell Weiss

Abbreviations



A-MDT	Accompanied MDT
СВО	Community-based Organization
CBR	Community-based Rehabilitation
CII	Critical Incident Investigation
DOT	Directly Observed Treatment
DSS	Decision Support System
EHF score	Eye Hand Feet score
G1D	Grade 1 Disability
G2D	Grade 2 Disability
GIS	Geographic Information System
GP	General Practitioner
GPS	Global Positioning System
HF	Health Facility
HIS	Health Information System
IEC	Information Education Communication
LEC	Leprosy Elimination Campaign
LEM	Leprosy Elimination Monitoring
MB	Multi Bacillary
MDT	Multidrug Therapy
M&E	Monitoring and Evaluation
NCDR	New Case-Detection Rate
NGO	Nongovernmental Organization
NTD	Neglected Tropical Disease
РВ	Pauci Bacillary
PC	Personal Computer
PD ratio	Prevalence/Detection Ratio



PHC	Primary Health Care
QA	Quality Assurance
RCS	Reconstructive Surgery
RFT	Release from Treatment
SAPEL	Special Action Project for Elimination of Leprosy
SHG	Self Help Group
SOAP	Subjective Objective Assessment Plan
ТВ	Tuberculosis
WER	Weekly Epidemiological Record
WHO	World Health Organization



https://www.yunbaogao.cn/report/index/re